Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
- Michael L. Wang, S. Rule, +28 authors K. Blum
- The New England journal of medicine
- 7 August 2013
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles. Expand
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. Expand
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for this very poor prognosis population. Expand
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma, and lend further support to the positive benefit-risk ratio for ibrut inib in relapsedor refractors. Expand
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy. Expand
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
- O. O’Connor, S. Horwitz, +14 authors A. Shustov
- Journal of clinical oncology : official journal…
- 22 June 2015
Monotherapy with belinostat produced complete and durable responses with manageable toxicity in patients with relapsed or refractory PTCL across the major subtypes, irrespective of number or type of prior therapies. Expand
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile. Expand
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
- W. Jurczak, K. Chojnowski, +4 authors L. F. Allen
- British journal of haematology
- 7 September 2018
The safety profile of avatrombopag was consistent with Phase 2 studies; the most common adverse events were headache and contusion. Expand
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Oral acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma, and suggest an important role for acAlabrUTinib in the treatment of this disease population. Expand
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
This study highlights the genetic heterogeneity in MCL, in particular at relapse, and provides for the first time genetic evidence of BCR/NF-κB activation in a subset of MCL. Expand